Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) - Net Assets
Based on the latest financial reports, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has net assets worth Rs2.76 Billion INR (≈ $29.87 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.17 Billion ≈ $34.25 Million USD) and total liabilities (Rs405.05 Million ≈ $4.38 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check JAGSNPHARM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs2.76 Billion |
| % of Total Assets | 87.21% |
| Annual Growth Rate | 7.09% |
| 5-Year Change | 111.05% |
| 10-Year Change | 151.26% |
| Growth Volatility | 8.46 |
Jagsonpal Pharmaceuticals Limited - Net Assets Trend (2006–2026)
This chart illustrates how Jagsonpal Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Jagsonpal Pharmaceuticals Limited.
Annual Net Assets for Jagsonpal Pharmaceuticals Limited (2006–2026)
The table below shows the annual net assets of Jagsonpal Pharmaceuticals Limited from 2006 to 2026. Also explore Jagsonpal Pharmaceuticals Limited net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs2.76 Billion ≈ $29.87 Million |
+15.10% |
| 2025-03-31 | Rs2.40 Billion ≈ $25.95 Million |
+28.04% |
| 2024-03-31 | Rs1.87 Billion ≈ $20.27 Million |
+17.94% |
| 2023-03-31 | Rs1.59 Billion ≈ $17.18 Million |
+21.42% |
| 2022-03-31 | Rs1.31 Billion ≈ $14.15 Million |
+7.32% |
| 2021-03-31 | Rs1.22 Billion ≈ $13.19 Million |
+9.81% |
| 2020-03-31 | Rs1.11 Billion ≈ $12.01 Million |
+6.28% |
| 2019-03-31 | Rs1.04 Billion ≈ $11.30 Million |
+6.55% |
| 2018-03-31 | Rs980.47 Million ≈ $10.60 Million |
-10.80% |
| 2017-03-31 | Rs1.10 Billion ≈ $11.89 Million |
+11.74% |
| 2016-03-31 | Rs983.64 Million ≈ $10.64 Million |
+3.08% |
| 2015-03-31 | Rs954.26 Million ≈ $10.32 Million |
-3.21% |
| 2014-03-31 | Rs985.89 Million ≈ $10.66 Million |
+0.22% |
| 2013-03-31 | Rs983.71 Million ≈ $10.64 Million |
-0.10% |
| 2012-03-31 | Rs984.69 Million ≈ $10.65 Million |
+5.98% |
| 2011-03-31 | Rs929.14 Million ≈ $10.05 Million |
+6.10% |
| 2010-03-31 | Rs875.70 Million ≈ $9.47 Million |
+9.23% |
| 2009-03-31 | Rs801.68 Million ≈ $8.67 Million |
+6.84% |
| 2008-03-31 | Rs750.34 Million ≈ $8.11 Million |
+3.50% |
| 2007-03-31 | Rs724.98 Million ≈ $7.84 Million |
+3.22% |
| 2006-03-31 | Rs702.35 Million ≈ $7.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jagsonpal Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs133.93 Million | 4.85% |
| Other Comprehensive Income | Rs2.63 Billion | 95.15% |
| Total Equity | Rs2.76 Billion | 100.00% |
Jagsonpal Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Jagsonpal Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
5paisa Capital Ltd
NSE:5PAISA
|
$162.92 Million |
|
HUYA Inc
F:HY5A
|
$162.92 Million |
|
Dynacor Gold Mines Inc.
TO:DNG
|
$162.93 Million |
|
Bank Ganesha Tbk PT
JK:BGTG
|
$162.93 Million |
|
Ellsworth Convertible Growth & IF
NYSE MKT:ECF
|
$162.75 Million |
|
SKYX Platforms Corp
NASDAQ:SKYX
|
$162.73 Million |
|
XINTE ENERGY CO. CL.H YC1
F:9M7
|
$162.72 Million |
|
Helloworld Travel Ltd
AU:HLO
|
$162.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jagsonpal Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 2,399,500,000 to 2,761,720,000, a change of 362,220,000 (15.1%).
- Net income of 430,820,000 contributed positively to equity growth.
- Dividend payments of 166,580,000 reduced retained earnings.
- New share issuances of 66,290,000 increased equity.
- Other comprehensive income increased equity by 1,994,080,000.
- Other factors decreased equity by 1,962,390,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs430.82 Million | +15.6% |
| Dividends Paid | Rs166.58 Million | -6.03% |
| Share Issuances | Rs66.29 Million | +2.4% |
| Other Comprehensive Income | Rs1.99 Billion | +72.2% |
| Other Changes | Rs-1.96 Billion | -71.06% |
| Total Change | Rs- | 15.10% |
Book Value vs Market Value Analysis
This analysis compares Jagsonpal Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.30x to 5.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs10.72 | Rs228.42 | x |
| 2007-03-31 | Rs11.07 | Rs228.42 | x |
| 2008-03-31 | Rs11.46 | Rs228.42 | x |
| 2009-03-31 | Rs12.24 | Rs228.42 | x |
| 2010-03-31 | Rs13.37 | Rs228.42 | x |
| 2011-03-31 | Rs14.19 | Rs228.42 | x |
| 2012-03-31 | Rs15.03 | Rs228.42 | x |
| 2013-03-31 | Rs15.02 | Rs228.42 | x |
| 2014-03-31 | Rs15.06 | Rs228.42 | x |
| 2015-03-31 | Rs14.57 | Rs228.42 | x |
| 2016-03-31 | Rs15.02 | Rs228.42 | x |
| 2017-03-31 | Rs16.78 | Rs228.42 | x |
| 2018-03-31 | Rs14.97 | Rs228.42 | x |
| 2019-03-31 | Rs15.95 | Rs228.42 | x |
| 2020-03-31 | Rs16.95 | Rs228.42 | x |
| 2021-03-31 | Rs18.62 | Rs228.42 | x |
| 2022-03-31 | Rs19.98 | Rs228.42 | x |
| 2023-03-31 | Rs24.26 | Rs228.42 | x |
| 2024-03-31 | Rs28.27 | Rs228.42 | x |
| 2025-03-31 | Rs35.63 | Rs228.42 | x |
| 2026-03-31 | Rs40.45 | Rs228.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jagsonpal Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.60%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.00%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.15x
- Recent ROE (15.60%) is above the historical average (7.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 3.74% | 1.69% | 1.10x | 2.02x | Rs-43.98 Million |
| 2007 | 3.87% | 2.17% | 0.88x | 2.03x | Rs-44.47 Million |
| 2008 | 4.10% | 2.05% | 1.15x | 1.74x | Rs-44.27 Million |
| 2009 | 7.70% | 4.53% | 1.11x | 1.53x | Rs-18.45 Million |
| 2010 | 10.55% | 6.62% | 1.13x | 1.41x | Rs4.85 Million |
| 2011 | 7.73% | 4.46% | 1.18x | 1.47x | Rs-21.12 Million |
| 2012 | 7.57% | 4.22% | 1.13x | 1.59x | Rs-23.90 Million |
| 2013 | 1.86% | 1.10% | 1.09x | 1.56x | Rs-80.04 Million |
| 2014 | 2.15% | 1.47% | 0.92x | 1.58x | Rs-77.38 Million |
| 2015 | 1.23% | 0.85% | 0.90x | 1.62x | Rs-83.71 Million |
| 2016 | 3.31% | 2.27% | 0.90x | 1.62x | Rs-65.82 Million |
| 2017 | 10.79% | 8.25% | 1.01x | 1.30x | Rs8.73 Million |
| 2018 | -11.78% | -9.13% | 0.97x | 1.32x | Rs-213.55 Million |
| 2019 | 6.91% | 4.33% | 1.23x | 1.30x | Rs-32.31 Million |
| 2020 | 7.09% | 4.96% | 1.08x | 1.32x | Rs-32.33 Million |
| 2021 | 13.99% | 9.08% | 1.14x | 1.35x | Rs48.65 Million |
| 2022 | 14.41% | 8.67% | 1.29x | 1.29x | Rs57.69 Million |
| 2023 | 16.82% | 11.29% | 1.21x | 1.23x | Rs108.32 Million |
| 2024 | 11.99% | 10.76% | 0.96x | 1.16x | Rs37.23 Million |
| 2025 | 23.07% | 20.60% | 0.97x | 1.16x | Rs313.66 Million |
| 2026 | 15.60% | 15.00% | 0.91x | 1.15x | Rs154.65 Million |
Industry Comparison
This section compares Jagsonpal Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $11,311,489,182
- Average return on equity (ROE) among peers: 24.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) | Rs2.76 Billion | 3.74% | 0.15x | $162.86 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $92.08 Million | 8.80% | 1.84x | $31.32 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $3.57 Billion | 19.23% | 2.08x | $426.21 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $17.57 Billion | 12.34% | 0.47x | $804.25 Million |
| Abbott India Limited (ABBOTINDIA) | $16.93 Billion | 23.70% | 0.43x | $6.27 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.57 Billion | 16.19% | 1.95x | $4.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $33.31 Billion | 7.66% | 0.64x | $1.30 Billion |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $7.07 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $933.00 Million | 99.03% | 0.19x | $154.33 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $2.95 Billion | 28.92% | 1.86x | $1.80 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $12.44 Billion | 8.06% | 2.40x | $10.79 Billion |
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more